Double maintains 1 strategies that include COGT - Cogent Biosciences, Inc.
Current Value
$6.011 Year Return
Current Value
$6.011 Year Return
Yahoo
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Yahoo
Four abstracts accepted for poster presentation highlight Cogent’s expertise in pioneering best-in-class therapeuticsWALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at the upcoming 2025 AACR Annual Meeting being held in Chicago, IL April 25-30, 2025. Poster Details Title: Identifica
Finnhub
WALTHAM, BOULDER - Cogent Biosciences, Inc. , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat...
Yahoo
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced expanded clinical results from the Open Label Extension
Yahoo
• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2nd-line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: C
Yahoo
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, 2025. The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclas
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BF.A | 0.10% | $15.61B | -36.74% | 2.70% |
AVO | -0.18% | $745.54M | -9.80% | 0.00% |
SYY | 0.22% | $36.90B | -6.23% | 2.69% |
WEC | 0.24% | $34.39B | +32.97% | 3.11% |
ZTO | 0.24% | $11.74B | -10.03% | 4.94% |
CMCSA | 0.24% | $138.84B | -12.17% | 3.43% |
MOMO | 0.26% | $827.19M | +8.19% | 0.00% |
STNG | 0.34% | $1.90B | -47.52% | 4.21% |
DOGZ | 0.35% | $354.30M | +315.37% | 0.00% |
GOGL | -0.35% | $1.66B | -34.31% | 12.64% |
QNTM | -0.36% | $15.34M | -81.65% | 0.00% |
KNDI | 0.36% | $119.68M | -35.68% | 0.00% |
IHRT | 0.37% | $223.71M | -24.00% | 0.00% |
MDLZ | 0.39% | $87.51B | -2.32% | 2.72% |
EH | 0.39% | $873.80M | +11.46% | 0.00% |
WBA | 0.49% | $9.65B | -40.38% | 6.74% |
ALAB | -0.50% | $10.06B | -14.13% | 0.00% |
GIS | -0.53% | $32.70B | -15.36% | 3.98% |
BF.B | -0.53% | $15.83B | -34.30% | 2.66% |
SRRK | -0.56% | $2.85B | +91.22% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -24.94% | $414.68M | 1.43% |
VIXY | -21.20% | $195.31M | 0.85% |
TAIL | -19.94% | $86.59M | 0.59% |
KMLM | -15.36% | $221.29M | 0.9% |
USDU | -12.31% | $207.14M | 0.5% |
UUP | -12.26% | $325.55M | 0.77% |
AGZD | -9.50% | $136.57M | 0.23% |
XHLF | -9.44% | $1.06B | 0.03% |
TPMN | -9.20% | $33.32M | 0.65% |
CTA | -8.50% | $964.37M | 0.76% |
DBE | -7.71% | $55.82M | 0.77% |
USL | -7.33% | $47.77M | 0.85% |
USO | -7.21% | $976.42M | 0.6% |
ULST | -7.18% | $587.14M | 0.2% |
BNO | -6.98% | $98.06M | 1% |
TFLO | -6.57% | $6.78B | 0.15% |
USFR | -5.91% | $18.50B | 0.15% |
OILK | -5.75% | $67.99M | 0.69% |
FLTR | -5.66% | $2.42B | 0.14% |
DBO | -5.62% | $202.31M | 0.77% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LITB | -19.10% | $41.37M | -43.18% | 0.00% |
CME | -13.93% | $94.51B | +22.09% | 3.99% |
INGR | -13.02% | $8.73B | +16.81% | 2.35% |
CBOE | -11.16% | $23.56B | +23.21% | 1.08% |
STVN | -10.21% | $5.70B | -32.12% | 0.28% |
PAYO | -9.95% | $2.69B | +53.07% | 0.00% |
SEG | -9.91% | $265.11M | -18.92% | 0.00% |
SCM | -8.90% | - | - | 11.51% |
PRT | -8.34% | $51.95M | +2.40% | 10.88% |
VZ | -8.17% | $191.04B | +6.68% | 5.93% |
PPC | -6.80% | $13.34B | +60.28% | 0.00% |
TCTM | -6.44% | $3.80M | -81.33% | 0.00% |
CL | -6.13% | $76.16B | +5.43% | 2.13% |
AEP | -5.85% | $57.87B | +27.18% | 3.33% |
MO | -5.53% | $99.39B | +36.94% | 6.89% |
KR | -5.47% | $49.31B | +17.85% | 1.83% |
KLG | -5.15% | $1.74B | +6.73% | 3.20% |
TRVG | -4.97% | $101.97M | +63.74% | 0.00% |
HRZN | -4.21% | - | - | 13.94% |
UUU | -4.06% | $4.12M | +9.88% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ARWR | 44.66% | $1.68B | -53.40% | 0.00% |
CRNX | 42.53% | $2.85B | -33.43% | 0.00% |
IDYA | 42.48% | $1.29B | -64.41% | 0.00% |
CLDX | 41.55% | $1.12B | -59.06% | 0.00% |
FATE | 40.80% | $86.76M | -88.87% | 0.00% |
XNCR | 40.65% | $682.78M | -54.95% | 0.00% |
DNTH | 40.06% | $540.67M | -36.94% | 0.00% |
RCKT | 39.64% | $619.52M | -77.39% | 0.00% |
ATXS | 39.42% | $304.74M | -57.81% | 0.00% |
CELC | 39.39% | $344.93M | -52.70% | 0.00% |
DNLI | 38.91% | $1.78B | -36.58% | 0.00% |
NTLA | 38.13% | $688.91M | -73.49% | 0.00% |
STOK | 37.61% | $336.90M | -52.37% | 0.00% |
KOD | 37.61% | $134.72M | -40.88% | 0.00% |
SYRE | 37.41% | $921.63M | -55.42% | 0.00% |
ROIV | 37.17% | $7.03B | -9.80% | 0.00% |
RARE | 37.04% | $3.13B | -27.37% | 0.00% |
LAW | 36.91% | $251.80M | -48.45% | 0.00% |
MQ | 36.78% | $2.14B | -29.64% | 0.00% |
MAX | 36.77% | $499.10M | -54.34% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 55.81% | $5.07B | 0.35% |
GNOM | 50.22% | $48.63M | 0.5% |
IBB | 49.83% | $5.74B | 0.45% |
PBE | 48.64% | $229.91M | 0.58% |
PTH | 44.44% | $111.59M | 0.6% |
ARKG | 43.81% | $963.54M | 0.75% |
IWC | 43.17% | $799.66M | 0.6% |
KJUL | 43.08% | $155.04M | 0.79% |
PINK | 41.40% | $141.58M | 0.5% |
IWO | 41.24% | $10.75B | 0.24% |
BBH | 41.11% | $365.93M | 0.35% |
XPH | 40.98% | $164.53M | 0.35% |
FBT | 40.69% | $1.11B | 0.56% |
IWM | 40.26% | $63.34B | 0.19% |
KAPR | 40.25% | $176.53M | 0.79% |
VTWO | 40.06% | $10.85B | 0.07% |
SCHA | 39.48% | $15.90B | 0.04% |
NUSC | 39.10% | $1.10B | 0.31% |
ESML | 38.68% | $1.75B | 0.17% |
ISCG | 38.48% | $652.91M | 0.06% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLRN | -0.42% | $2.82B | 0.15% |
DBC | -0.45% | $1.36B | 0.87% |
TBIL | -0.48% | $5.35B | 0.15% |
IBMO | 0.63% | $506.25M | 0.18% |
XBIL | 0.75% | $708.50M | 0.15% |
PDBC | -0.84% | $4.88B | 0.59% |
KRBN | -0.95% | $172.14M | 0.85% |
GBIL | -0.98% | $6.31B | 0.12% |
IBTP | -1.09% | $109.02M | 0.07% |
TAXF | 1.12% | $516.85M | 0.29% |
WEAT | 1.21% | $115.01M | 0.28% |
FMF | 1.38% | $154.57M | 0.95% |
CCOR | -1.44% | $64.32M | 1.18% |
SGOV | -1.58% | $39.39B | 0.09% |
GSG | -1.81% | $1.05B | 0.75% |
BILS | 1.86% | $3.65B | 0.1356% |
USCI | -1.92% | $237.61M | 1.07% |
BIL | -2.02% | $41.05B | 0.1356% |
CLOZ | -2.04% | $800.70M | 0.5% |
KCCA | 2.17% | $109.09M | 0.87% |